Skip to main content

Advertisement

Table 2 Exposure to angiotensin II receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors and their relative risk for acute pancreatitis estimated by odds ratio (OR) with 95% confidence intervals (CI)

From: Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden

Exposure Controls Cases Model 1a Model 2b Model 3c
N (%) N (%) OR 95% CI OR 95% CI OR 95% CI
Total 61,637 (100) 6,161 (100)    
ARB      
  Never use 56,542 (92) 5,571 (90) 1 (reference) 1 (reference) 1 (reference)
  Current use 4,715 (8) 548 (9) 1 · 18 (1 · 08–1 · 30) 0 · 82 (0 · 74–0 · 90) 0 · 77 (0 · 69–0 · 86)
  Past use 380 (1) 42 (1) 1 · 13 (0 · 82–1 · 55) 0 · 77 (0 · 74–0 · 90) 0 · 70 (0 · 49–1 · 01)
ACE-inhibitors      
  Never use 55,073 (89) 5,080 (82) 1 (reference) 1 (reference) 1 (reference)
  Current use 6,067 (10) 987 (16) 1 · 82 (1 · 69–1 · 96) 1 · 16 (1 · 07–1 · 26) 1 · 11 (1 · 01–1 · 21)
  Past use 497 (1) 94 (2) 2 · 11 (1 · 69–2 · 63) 1 · 37 (1 · 09–1 · 72) 1 · 24 (0 · 95–1 · 60)
  1. aAdjusting for sex, age and calendar year. bAs Model 1 + presence of cardiovascular disorder
  2. cAdjusting for sex, age, calendar year, education, alcohol related disease, gallstone disease, chronic obstructive pulmonary disease, diabetes, cardiovascular disorder, and number of distinct medications, Angiotensin-converting enzyme (ACE)-inhibitors and ARB